Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

The projected decline in GLAND's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.00000
forwardPE 25.29622
debtToEquity 3.16100
earningsGrowth 0.27800
revenueGrowth 0.22500
grossMargins 0.58863
operatingMargins 0.19302
trailingEps 51.37000
forwardEps 72.01471

GLAND's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
GLAND's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with GLAND expected to continue increasing its profits and revenue in the coming periods.
GLAND's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that GLAND's financial performance will improve in the current financial year.

Price projections:

Price projections for GLAND
Price projections for GLAND

Gland Pharma Limited's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


5 separate sales of GLAND shares were executed, with the market price hovering at 1913.4599853515624.There were no sell transactions during the period under consideration.GLAND has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


Analysts have maintained a buy bias for GLAND, which could prompt investors to consider the stock as a viable investment. With this positive outlook, GLAND is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.